Sign in
Not yet recruitingPhase 2

New PET scan tracer to spot heart inflammation in cardiac sarcoidosis

Tests a new scan tracer for finding heart inflammation in people with cardiac sarcoidosis.

Key facts

Who runs it
Cliniques Universitaires Saint-Luc
Where
Belgium1 site in 1 countryChoose a country to see its sites
Registry title
Study on the detection of cardiac inflammation by PET-CT imaging with a new tracer called '68Ga-NOTA-Anti-MMR-VHH2' in patients with cardiac sarcoidosis.
Status
Not yet recruiting
Phase
Phase 2
People taking part
15 people, planned
Started
30 Sept 2024
Planned end
30 Jun 2026
Type of study
Interventional
Record updated
25 September 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cardiac sarcoidosis, an inflammation of the heart. It tests a new PET/CT scan tracer called 68Ga-NOTA-Anti-MMR-VHH2.

Age
18 years and older
Sex
Men and women
Disease stage
Cardiac sarcoidosis proven by biopsy, or a probable diagnosis based on the HRS 2014 consensus criteria.
Earlier treatment
You must already have had an 18F-FDG PET/CT scan, not older than 1 month before screening, showing a patchy pattern typical of cardiac sarcoidosis. You must also have had a 13N-NH3 PET/CT scan, not older than 1 month before screening.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • ECOG performance status 3 or 4 (very limited in daily activity)
  • Poor organ function, for example estimated GFR <30 ml/min/1.73m2 or low neutrophil count
  • Life expectancy <6 months or another life-threatening illness
  • Cannot have contrast MRI or PET/CT, or does not speak or understand French or Dutch

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Male and female patients at least 18 years old
  • Patients with biopsy proven or probable diagnosis of cardiac sarcoidosis based on the HRS 2014 consensus criteria
  • Having available the following historical diagnostic images: o 18F-FDG PET/CT scan (Standard of care), not older than 1 month prior to screening, with patchy pattern consistent of CS o 13N-NH3 PET/CT scan (Standard of care), not older than 1 month prior to screening
  • Male patients able to father children and female patients of childbearing potential agree to use effective methods of contraception during the study

Who cannot take part

  • Patients at increased risk of death from a pre-existing concurrent illness with life expectancy <6 months
  • Patients who have any other life-threatening illness, which in the opinion of the investigator would either compromise patient safety
  • Patients with contra-indications for contrast enhanced MRI and PET/CT (e.g. size, claustrophobia, known clinically relevant hypersensitivity reactions to gadolinium,…)
  • Patients with any other condition that in the opinion of the investigator may significantly interfere with study compliance (including but not limited to psychological or psychiatric, social or geographical condition potentially hampering compliance with the study requirements)
  • Patients with inadequate organ function, suggested by the following laboratory results drawn at screening: o Significantly impaired renal function defined as estimated GFR <30 ml/min/1.73m2. o Absolute neutrophil count <1,500 cells/mm3. o Total bilirubin >1.5 x Upper Limit of Normal (ULN) (unless the patient has documented Gilbert's syndrome). o Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or Alanine aminotransferase (ALT)/ serum glutamic pyruvic transaminase (SGPT) >3.0 x ULN
  • Patients with Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4
  • Pregnant patients / breast feeding patients
  • Patients who do not speak/ understand French or Dutch

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluate the ability of in vivo 68Ga-NOTA-Anti-MMR-VHH2 PET/CT imaging to detect cardiac sarcoid lesions in patients with histological or clinical ‘probable’ diagnosis of cardiac sarcoidosis based on the HRS 2014 criteria including a patchy pattern on FDG-PET/CT consistent with cardiac sarcoidosis.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Phase II study to assess in vivo imaging of MMR-expressing macrophages in cardiac sarcoidosis using 68Ga-NOTA-Anti-MMR-VHH2 Positron Emission Tomography (PET).
Plain-language title
New PET scan tracer to spot heart inflammation in cardiac sarcoidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
25 September 2024